2-ACYLAMINOPROPOANOL-TYPE GLUCOSYLCERAMIDE SYNTHASE INHIBITORS
2 Assignments
0 Petitions
Accused Products
Abstract
A compound is represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. The subject has type 2 diabetes; renal hypertrophy or hyperplasia associated with diabetic nephropathy; Tay-Sachs; Gaucher'"'"'s; or Fabry'"'"'s disease. Methods of decreasing plasma TNF-α, lowering blood glucose levels, decreasing glycated hemoglobin levels, inhibiting glucosylceramide synthase, and lowering glycosphingolipid concentrations in a subject in need thereof respectively comprise administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.
62 Citations
108 Claims
-
1-89. -89. (canceled)
- 90. A compound represented by the following structural formula:
-
105. A compound represented by the following structural formula:
-
106. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound represented by the following structural formula:
-
107. A method of treating a subject having type 2 diabetes;
- renal hypertrophy or hyperplasia associated with diabetic nephropathy;
Tay-Sachs, Gaucher'"'"'s or Fabry'"'"'s disease, comprising administering to the subject a therapeutically effective amount of a compound represented by the following structural formula;
- renal hypertrophy or hyperplasia associated with diabetic nephropathy;
-
108. A method of decreasing plasma TNF-α
- ;
of lowering blood glucose levels;of decreasing glycated hemoglobin levels, or of inhibiting glucosylceramide synthase or lowering glycosphingolipid concentrations in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound represented by the following structural formula;
- ;
Specification